Diffuse Leukoplakia of the Bladder Ostium-Sparing in Patient Treated with Leuprorelin for Breast Cancer.

Case Reports in Urology Pub Date : 2021-07-27 eCollection Date: 2021-01-01 DOI:10.1155/2021/9970711
Antonio Nacchia, Ferdinando di Giacomo, Arcangelo Di Cerbo, Massimo Dante Di Somma, Giuseppe Patitucci, Giuseppe Disabato, Giulia Vita
{"title":"Diffuse Leukoplakia of the Bladder Ostium-Sparing in Patient Treated with Leuprorelin for Breast Cancer.","authors":"Antonio Nacchia,&nbsp;Ferdinando di Giacomo,&nbsp;Arcangelo Di Cerbo,&nbsp;Massimo Dante Di Somma,&nbsp;Giuseppe Patitucci,&nbsp;Giuseppe Disabato,&nbsp;Giulia Vita","doi":"10.1155/2021/9970711","DOIUrl":null,"url":null,"abstract":"<p><strong>Case: </strong>A 55-year-old woman came to our attention in April 2020 referring haematuria, frequency and urgency. The patient referred previous treatment with leuprorelin 3.75 mg/2 ml for breast cancer three years ago. Urine culture was performed and resulted always negative for pathogens. Cystoscopy revealed a whitish plaque lesion on the fundus, dome, trigone, and left lateral wall of the bladder. Histology of the biopsy confirmed the diagnosis of leukoplakia of the bladder. The plan is to follow her up repeating a cystoscopy every three months and biopsy in 6 months. Literature search revealed very little information on pathogenesis and prognosis of this condition due to its rare occurrence. The main objective of our case study was to describe individual situation of a woman affected by diffuse leukoplakia of the bladder ostium-sparing with a previous treatment with leuprorelin 3.75 mg/2 ml for breast cancer and to show safety of follow-up by cystoscopy and biopsy.</p><p><strong>Conclusions: </strong>We showed a case of a woman treated with leuprorelin and with diffuse leukoplakia of the bladder. We support the recommended long-term follow-up and surveillance based on the literature review by cystoscopy with or without biopsy.</p>","PeriodicalId":30323,"journal":{"name":"Case Reports in Urology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8337129/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/9970711","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Case: A 55-year-old woman came to our attention in April 2020 referring haematuria, frequency and urgency. The patient referred previous treatment with leuprorelin 3.75 mg/2 ml for breast cancer three years ago. Urine culture was performed and resulted always negative for pathogens. Cystoscopy revealed a whitish plaque lesion on the fundus, dome, trigone, and left lateral wall of the bladder. Histology of the biopsy confirmed the diagnosis of leukoplakia of the bladder. The plan is to follow her up repeating a cystoscopy every three months and biopsy in 6 months. Literature search revealed very little information on pathogenesis and prognosis of this condition due to its rare occurrence. The main objective of our case study was to describe individual situation of a woman affected by diffuse leukoplakia of the bladder ostium-sparing with a previous treatment with leuprorelin 3.75 mg/2 ml for breast cancer and to show safety of follow-up by cystoscopy and biopsy.

Conclusions: We showed a case of a woman treated with leuprorelin and with diffuse leukoplakia of the bladder. We support the recommended long-term follow-up and surveillance based on the literature review by cystoscopy with or without biopsy.

Abstract Image

Abstract Image

Abstract Image

Leuprorelin治疗乳腺癌患者膀胱开口保留的弥漫性白斑。
病例:2020年4月,一名55岁女性因血尿、尿频和尿急入院。该患者三年前因乳腺癌接受leuprorelin 3.75 mg/2 ml治疗。尿培养结果均为阴性。膀胱镜检查发现眼底、膀胱穹窿、膀胱三角区和膀胱左侧壁有白色斑块病变。组织活检证实了膀胱白斑的诊断。计划是每三个月复查一次膀胱镜检查,六个月复查一次活检。文献检索显示,由于其罕见的发病机制和预后的信息很少。本病例研究的主要目的是描述一名既往使用leuprorelin 3.75 mg/2 ml治疗乳腺癌的女性膀胱弥漫性白斑的个体情况,并显示膀胱镜检查和活检随访的安全性。结论:我们报告了一例接受leuprorelin治疗的女性膀胱弥漫性白斑。我们支持推荐的长期随访和监测,基于文献综述,膀胱镜检查伴或不伴活检。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
28
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信